1. Zumoff B, et al. Age variation of the 24-hour mean plasma concentrations of androgens, estrogens, and gonadotropins in normal adult men. J Clin Endocrinol Metab 1982;54((3):534-538.
3. Christiansen JS, et al. Effects of growth hormone on body composition in adults. Horm Res 1990;33 Suppl 4:61-64.
4. Holcombe JH, et al. Biosynthetic human growth hormone in the treatment of growth hormone deficiency. Acta Paediatr Scand Suppl 1990;367:44-48.
5. Shi YF, et al. Treatment of growth hormone deficient patients with recombinant somatropin for 1 year: results of a Chinese multicentre trial. Acta Paediatr Scand Suppl 1990;370:212-215.
6. Huether G. Melatonin as an antiaging drug: between facts and fantasy. Gerontology 1996;42((2):87-86.
7. Raben M. The clinical use of growth hormone. NEJM 1962;266:82-86.
8. Rosen T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990;336((8710):285-288.
9. Bengtsson BA, et al. Treatment of adults with growth hormone(GH) deficiency with recombinant human GH. J Clin Endocrinol Metab 1993;76((2):309-317.
10. Snel YE, et al. Adipose tissue assessed by magnetic resonance imaging in growth hormone-deficient adults: the effect of growth hormone replacement and a comparison with control subjects. Am J Clin Nutr 1995;61((6):1290-1294.
11. de Boer H, et al. Changes in subcutaneous and visceral fat mass during growth hormone replacement therapy in adult men. Int J Obes Relat Metab Disord 1996;20((6):580-587.
12. Marcus R, Hoffman AR. Growth hormone as therapy for older men and women. Annu Rev Pharmacol Toxicol 1998;38:45-61.
13. Cummings DE, Merriam GR. Age-related changes in growth hormone secretion: should the somatopause be treated? Semin Reprod Endocrinol 1999;17((4):311-325.
14. Wang Z. Growth hormone deficiency in adults and clinical use of recombinant human growth hormone. Chin Med J (Engl) 1999;112((3):195-201.
15. Eden S, et al. Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations. Arterioscler Thromb 1993;13((2):296-301.
16. Garry P, Collins P, Devlin JG. An open 36-month study of lipid changes with growth hormone in adults: lipid changes following replacement of growth hormone in adult acquired growth hormone deficiency. Eur J Endocrinol 1996;134((1):61-66.
18. Hassan HM, et al. Body composition, atherogenic risk factors and apolipoproteins following growth hormone treatment. Acta Paediatr 1996;85((8):899-901.
19. Lucidi P, et al. A dose-response study of growth hormone (GH) replacement on whole body protein and lipid kinetics in GH-deficient adults. J Clin Endocrinol Metab 1998;83((2):353-357.
21. Bengtsson BA, et al. The effects of treatment and the individual responsiveness to growth hormone(GH) replacement therapy in 665 GH-deficient adults. KIMS Study Group and the KIMS International Board. J Clin Endocrinol Metab 1999;84((11):3929-3935.
22. Chrisoulidou A, et al. Effects of growth hormone treatment on very-low density lipoprotein apolipoprotein B100 turnover in adult hypopituitarism. Metabolism 2000;49((5):563-566.
23. Wieringa G, et al. Changes in lipoprotein(a) levels measured by six kit methods during growth hormone treatment of growth hormone-deficient adults. Growth Horm IGF Res 2000;10((1):14-19.
24. Johannsson G, et al. Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency. J Clin Endocrinol Metab 1996;81((8):2865-2873.
25. Baum HB, et al. Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial. Ann Intern Med 1996;125((11):883-890.
26. Burman P, et al. Growth hormone(GH)-deficient men are more responsive to GH replacement therapy than women. J Clin Endocrinol Metab 1997;82((2):550-555.
27. Janssen YJ, et al. Skeletal effects of two years of treatment with low physiological doses of recombinant human growth hormone(GH) in patients with adult-onset GH deficiency. J Clin Endocrinol Metab 1998;83((6):2143-2148.
28. Johannsson G, Ohlsson C. Growth hormone therapy and fracture risk in the growth hormone-deficient adult. Baillieres Clin Endocrinol Metab 1998;12((2):233-250.
30. Gotherstrom G, et al. A prospective study of 5 years of GH replacement therapy in GH-deficient adults: sustained effects on body composition, bone mass, and metabolic indices. J Clin Endocrinol Metab 2001;86((10):4657-4665.
31. Cuneo RC, et al. Growth hormone treatment in growth hormone-deficient adults. II. Effects on exercise performance. J Appl Physiol 1991;70((2):695-700.
32. Jorgensen JO, et al. Adult growth hormone deficiency. Horm Res 1994;42((4-5):235-241.
33. Weaver JU, et al. The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hypopituitary adults. J Clin Endocrinol Metab 1995;80((1):153-159.
34. Johansson JO, et al. Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults. Thromb Haemost 1996;76((3):422-428.
35. Johannsson G, et al. Long-term cardiovascular effects of growth hormone treatment in GH-deficient adults. Preliminary data in a small group of patients. Clin Endocrinol (Oxf) 1996;45((3):305-314.
36. Bozzola M, et al. In vitro and in vivo effect of growth hormone on cytotoxic activity. J Pediatr 1990;117((4):596-599.
37. Benfield MR, et al. The effect of rhGH in vitro on donor-specific hyporesponsiveness in pediatric transplantation. Pediatr Transplant 1997;1((1):90-97.
38. McKenna SPA, LC Doward. Quality-of-life assessment of adults with growth hormone deficiency. Implications for drug therapy. Pharmacoeconomics 1994;6((5):434-441.
39. Beshyah SA, et al. Replacement treatment with biosynthetic human growth hormone in growth hormone-deficient hypopituitary adults. Clin Endocrinol (Oxf) 1995;42((1):73-84.
42. Chrisoulidou A, et al. How much, and by what mechanisms, does growth hormone replacement improve the quality of life in GH-deficient adults? Baillieres Clin Endocrinol Metab 1998;12((2):261-279.
43. Deijen JB, van der Veen EA. The influence of growth hormone (GH)-deficiency and GH replacement on quality of life in GH-deficient patients. J Endocrinol Invest 1999;22 Suppl 5:127-136.
44. Monson JP, et al. Growth hormone deficiency and replacement in elderly hypopituitary adults. KIMS Study Group and the KIMS International Board. Pharmacia and Upjohn International Metabolic Database. Clin Endocrinol (Oxf) 2000;53((3):281-289.
45. McGauley G. The psychological consequences and quality of life in adults with growth hormone deficiency. Growth Horm IGF Res 2000;10 Suppl B:s63-s68.
46. Sönksen PH, Christiansen JS. . Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency. Growth Horm IGF Res 1998;8 Suppl B:89-92.
47. de Boer H, et al. Monitoring of growth hormone replacement therapy in adults, based on measurement of serum markers. J Clin Endocrinol Metab 1996;81((4):1371-1377.
48. Verhelst J, et al. Two years of replacement therapy in adults with growth hormone deficiency. Clin Endocrinol (Oxf) 1997;47(4)((4):485-494.
49. Chrisoulidou A, et al. Effects of 7 years of growth hormone replacement therapy in hypopituitary adults. J Clin Endocrinol Metab 2000;85((10):3762-3769.
50. Hatrick AG, et al. Does GH replacement therapy in adult GH-deficient patients result in recurrence or increase in size of pituitary tumours? Eur J Endocrinol 2002;146((6):807-811.